H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on ATXS stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily centered around the promising initial data from Astria Therapeutics’ STAR-0310. The Phase 1a study results presented at the European Academy of Dermatology and Venereology demonstrated that STAR-0310, a monoclonal antibody antagonist of OX40, has shown potential as a best-in-class treatment for atopic dermatitis. The study highlighted STAR-0310’s extended half-life of 68 days and sustained cytokine suppression for at least 20 weeks, indicating the possibility of administration every six months.
Additionally, the biomarker results revealed robust target engagement, with STAR-0310 modulating a broad spectrum of immune pathways beyond Th-2 for a long duration. The treatment was well-tolerated, with no adverse events related to antibody-dependent cellular cytotoxicity, suggesting a wider therapeutic window compared to existing OX40 antagonists. This wider therapeutic window could lead to lasting efficacy, especially for patients who do not respond to current approved biologics. With a large commercial market opportunity and anticipated updates on the STAR-0310 program, Pantginis sees a viable opportunity for Astria to expand its pipeline.
According to TipRanks, Pantginis is an analyst with an average return of -4.0% and a 41.68% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Krystal Biotech, and Lineage Therap.
In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $49.00 price target.